Advertisement
Canada markets open in 2 hours 6 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7308
    -0.0012 (-0.17%)
     

  • CRUDE OIL

    82.72
    -0.64 (-0.77%)
     

  • Bitcoin CAD

    90,849.77
    +371.63 (+0.41%)
     

  • CMC Crypto 200

    1,434.89
    +10.79 (+0.76%)
     

  • GOLD FUTURES

    2,328.00
    -14.10 (-0.60%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,706.50
    +99.75 (+0.57%)
     

  • VOLATILITY

    15.84
    +0.15 (+0.96%)
     

  • FTSE

    8,084.43
    +39.62 (+0.49%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6834
    -0.0002 (-0.03%)
     

Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit

Monte Rosa Therapeutics, Inc.
·1 min read

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Sharon Townson, Ph.D., Chief Technology Officer, will present at the virtual 4th Annual Targeted Protein Degradation Summit on Wednesday, Oct. 27 at 11:45 a.m. ET. The presentation, titled, “Molecular Glue Degraders: From Serendipity to Rational Design,” will showcase the capabilities of Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform and its impact on expanding target space.

The presentation will be archived under the “Events & Presentations” section of the Company’s investors section of the website at https://ir.monterosatx.com/.

About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader precision medicines. These medicines are designed to employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates), that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, AI/machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.

Contacts:

Investors
Michael Morabito, Solebury Trout
ir@monterosatx.com

Media
Dan Budwick, 1AB
dan@1abmedia.com